HFE gene variants affect iron in the brain

Journal of Nutrition

Volumn 141, Issue 4, 2011, Pages

  Nandar, Wint ^a   Connor, James R ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HFE PROTEIN; IRON;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; BRAIN REGION; CONFERENCE PAPER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRON OVERLOAD; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; PROTEIN STRUCTURE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; MEMBRANE PROTEINS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 79955492902     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.110.130351     Document Type: Conference Paper

References (128)

1. Wigglesworth JMBH. Iron dependent enzymes in the brain. In: Youdim MB, editor. Brain iron: neurochemical and behavioural aspects. New York: Taylor and Francis; 1988. p. 25-66.
2. Beard JL, Connor JR, Jones BC. Iron in the brain. Nutr Rev. 1993;51: 157-70.
3. Beard JL. Why iron deficiency is important in infant development. J Nutr. 2008;138:2534-6.
4. Salvador GA. Iron in neuronal function and dysfunction. Biofactors. 2010;36:103-10.
5. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609-23.
6. Levenson CW, Tassabehji NM. Iron and ageing: an introduction to iron regulatory mechanisms. Ageing Res Rev. 2004;3:251-63.
7. Johnstone D, Milward EA. Molecular genetic approaches to understanding the roles and regulation of iron in brain health and disease. J Neurochem. 2010;113:1387-402.
8. Beutler E, Felitti V, Gelbart T, Ho N. Genetics of iron storage and hemochromatosis. Drug Metab Dispos. 2001;29:495-9.
9. Connor JR, Lee SY. HFE mutations and Alzheimer's disease. J Alzheimers Dis. 2006;10:267-76.
10. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5: 863-73.
11. Benarroch EE. Brain iron homeostasis and neurodegenerative disease. Neurology. 2009;72:1436-40.
12. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958;3:41-51.
13. Aoki S, Okada Y, Nishimura K, Barkovich AJ, Kjos BO, Brasch RC, Norman D. Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology. 1989;172:381-5.
14. Bartzokis G, Beckson M, Hance DB, Marx P, Foster JA, Marder SR. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging. 1997;15:29-35.
15. Connor JR, Menzies SL. Cellular management of iron in the brain. J Neurol Sci. 1995;134 Suppl:33-44.
16. Thompson KJ, Shoham S, Connor JR. Iron and neurodegenerative disorders. Brain Res Bull. 2001;55:155-64.
17. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis. 2009;16:879-95.
18. Chen Q, Connor JR, Beard JL. Brain iron, transferrin and ferritin concentrations are altered in developing iron-deficient rats. J Nutr. 1995;125:1529-35.
19. Sheldon JH. Hemochromatosis. London: Oxford University Press; 1935. p. 155-9.
20. Cammermyer J. Deposition of iron in paraventricular areas of the human brain in hemochromatosis. J Neuropathol Exp Neurol. 1947;6: 111-27.
21. Nielsen JE, Jensen LN, Krabbe K. Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. J Neurol Neurosurg Psychiatry. 1995;59:318-21.
22. Berg D, Hoggenmuller U, Hofmann E, Fischer R, Kraus M, Scheurlen M, Becker G. The basal ganglia in haemochromatosis. Neuroradiology. 2000;42:9-13.
23. Rutgers MP, Pielen A, Gille M. Chronic cerebellar ataxia and hereditary hemochromatosis: causal or coincidental association? J Neurol. 2007;254:1296-7.
24. Connor JR, Milward EA, Moalem S, Sampietro M, Boyer P, Percy ME, Vergani C, Scott RJ, Chorney M. Is hemochromatosis a risk factor for Alzheimer's disease? J Alzheimers Dis. 2001;3:471-7.
25. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: metaanalyses including 66,000 cases and 226,000 controls. Hepatology. 2007;46:1071-80.
26. Simon M, Bourel M, Fauchet R, Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut. 1976;17: 332-4.
27. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408.
28. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34:275-8.
29. Weiss G. Genetic mechanisms and modifying factors in hereditary hemochromatosis. Nat Rev Gastroenterol Hepatol. 2010;7:50-8.
30. Alexander J, Kowdley KV. HFE-associated hereditary hemochromatosis. Genet Med. 2009;11:307-13.
31. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, et al. Iron-overloadrelated disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221-30.
32. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJ. Geography of HFE C282Y and H63D mutations. Genet Test. 2000;4:183-98.
33. Lebron JA, Bennett MJ, Vaughn DE, Chirino AJ, Snow PM, Mintier GA, Feder JN, Bjorkman PJ. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell. 1998;93:111-23.
34. Bennett MJ, Lebron JA, Bjorkman PJ. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature. 2000;403:46-53.
35. Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem. 1990; 59:253-88.
36. Miyazaki J, Appella E, Ozato K. Intracellular transport blockade caused by disruption of the disulfide bridge in the third external domain of major histocompatibility complex class I antigen. Proc Natl Acad Sci USA. 1986;83:757-61.
37. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, Morikang E, Prass CE, Starnes SM, Wolff RK, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem. 1997;272:14025-8.
38. Waheed A, Parkkila S, Zhou XY, Tomatsu S, Tsuchihashi Z, Feder JN, Schatzman RC, Britton RS, Bacon BR, et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA. 1997;94:12384-9.
39. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, Tsuchihashi Z, Sigal E, Bjorkman PJ, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA. 1998;95:1472-7.
40. Lebron JA, Bjorkman PJ. The transferrin receptor binding site on HFE, the class I MHC-related protein mutated in hereditary hemochromatosis. J Mol Biol. 1999;289:1109-18.
41. Lebron JA, West AP Jr, Bjorkman PJ. The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol. 1999;294:239-45.
42. Roy CN, Custodio AO, de Graaf J, Schneider S, Akpan I, Montross LK, Sanchez M, Gaudino A, Hentze MW, et al. An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharideinduced inflammation in mice. Nat Genet. 2004;36:481-5.
43. Wang L, Johnson EE, Shi HN,WalkerWA,Wessling-ResnickM, Cherayil BJ. Attenuated inflammatory responses in hemochromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol. 2008;181:2723-31.
44. Lee SY, Patton SM, Henderson RJ, Connor JR. Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE. FASEB J. 2007;21: 564-76.
45. Mitchell RM, Lee SY, Simmons Z, Connor JR. HFE polymorphisms affect cellular glutamate regulation. Neurobiol Aging. Epub 2009 Jun 25.
46. Mitchell RM, Lee SY, Randazzo WT, Simmons Z, Connor JR. Influence of HFE variants and cellular iron on monocyte chemoattractant protein-1. J Neuroinflammation. 2009;6:6.
47. Selim MH, Ratan RR. The role of iron neurotoxicity in ischemic stroke. Ageing Res Rev. 2004;3:345-53.
48. Bastin JM, Jones M, O'Callaghan CA, Schimanski L, Mason DY, Townsend AR. Kupffer cell staining by an HFE-specific monoclonal antibody: implications for hereditary haemochromatosis. Br J Haematol. 1998;103:931-41.
49. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996;335:1799-805.
50. Burt MJ, George PM, Upton JD, Collett JA, Frampton CM, Chapman TM, Walmsley TA, Chapman BA. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut. 1998;43:830-6.
51. Datz C, Haas T, Rinner H, Sandhofer F, Patsch W, Paulweber B. Heterozygosity for the C282Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: a protective role against iron deficiency? Clin Chem. 1998;44:2429-32.
52. Bartzokis G, Lu PH, Tishler TA, Peters DG, Kosenko A, Barrall KA, Finn JP, Villablanca P, Laub G, et al. Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J Alzheimers Dis. 2010;20:333-41.
53. Oba H, Araki T, Ohtomo K, Monzawa S, Uchiyama G, Koizumi K, Nogata Y, Kachi K, Shiozawa Z, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex atMR imaging. Radiology. 1993;189:843-6.
54. Kasarskis EJ, Tandon L, Lovell MA, Ehmann WD. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J Neurol Sci. 1995;130:203-8.
55. Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ, Nguyen H, Brickman CM, LeWitt PA. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem. 1995;65:710-24.
56. Barber SC, Mead RJ, Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta. 2006;1762:1051-67.
57. Wang XS, Lee S, Simmons Z, Boyer P, Scott K, Liu W, Connor J. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci. 2004;227:27-33.
58. Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, Schoenfeld DA, Hosler BA, Horvitz HR, et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41:210-21.
59. Goodall EF, Greenway MJ, van Marion I, Carroll CB, Hardiman O, Morrison KE. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology. 2005;65:934-7.
60. Restagno G, Lombardo F, Ghiglione P, Calvo A, Cocco E, Sbaiz L, Mutani R, Chio A. HFE H63D polymorphism is increased in patients with amyotrophic lateral sclerosis of Italian origin. J Neurol Neurosurg Psychiatry. 2007;78:327.
61. Sutedja NA, Sinke RJ, Van Vught PW, Van der Linden MW, Wokke JH, Van Duijn CM, Njajou OT, Van der Schouw YT, Veldink JH, et al. The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch Neurol. 2007;64:63-7.
62. He X, Lu X, Hu J, Xi J, Zhou D, Shang H, Liu L, Zhou H, Yan B, et al. H63D polymorphism in the hemochromatosis gene is associated with sporadic amyotrophic lateral sclerosis in China. Eur J Neurol. Epub 2010 Jul 19.
63. Yen AA, Simpson EP, Henkel JS, Beers DR, Appel SH. HFE mutations are not strongly associated with sporadic ALS. Neurology. 2004;62: 1611-2.
64. Yasui M, Ota K, Garruto RM. Concentrations of zinc and iron in the brains of Guamanian patients with amyotrophic lateral sclerosis and parkinsonism-dementia. Neurotoxicology. 1993;14:445-50.
65. Markesbery WR, Ehmann WD, Candy JM, Ince PG, Shaw PJ, Tandon L, Deibel MA. Neutron activation analysis of trace elements in motor neuron disease spinal cord. Neurodegeneration. 1995;4:383-90.
66. Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, David S. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci. 2009;29:610-9.
67. Goodall EF, Haque MS, Morrison KE. Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. J Neurol. 2008;255: 1652-6.
68. Mitchell RM, Simmons Z, Beard JL, Stephens HE, Connor JR. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve. 2010;42:95-103.
69. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3.
70. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65 Suppl 1:S3-9.
71. Hall EC II, Lee SY, Mairuae N, Simmons Z, Connor JR. Expression of the HFE allelic variant H63D in SH-SY5Y cells affects tau phosphorylation at serine residues. Neurobiol Aging. Epub 2009 Sep 21.
72. Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:91-6.
73. Molfino A, Kushta I, Tommasi V, Rossi Fanelli F, Muscaritoli M. Amyotrophic lateral sclerosis, enteral nutrition and the risk of iron overload. J Neurol. 2009;256:1015-6.
74. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6:1045-53.
75. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 2002;13:1067-70.
76. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002;10:268-78.
77. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417:74-8.
78. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003;53:267-70.
79. Smith MA, Sayre LM, Vitek MP, Monnier VM, Perry G. Early ageing and Alzheimer's. Nature. 1995;374:316.
80. Mattson MP, Carney JW, Butterfield DA. A tombstone in Alzheimer's? Nature. 1995;373:481.
81. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW Jr, Cohen ML, Wang X, Siedlak SL, Dwyer BE, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis. 2010;19:363-72.
82. Rivera-Mancia S, Perez-Neri I, Rios C, Tristan-Lopez L, Rivera-Espinosa L, Montes S. The transition metals copper and iron in neurodegenerative diseases. Chem Biol Interact. 2010;186:184-99.
83. Bodovitz S, Falduto MT, Frail DE, Klein WL. Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. J Neurochem. 1995;64:307-15.
84. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, Smith MA. Redox-active iron mediates amyloidbeta toxicity. Free Radic Biol Med. 2001;30:447-50.
85. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, et al. An iron-responsive element type II in the 59-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002;277:45518-28.
86. Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, Rogers JT. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem. 2010;285:31217-32.
87. Lee SY, Connor JR. Regulation of Hfe by stress factors in BV-2 cells. Neurobiol Aging. 2005;26:803-12.
88. Hall EC II, Lee SY, Simmons Z, Neely EB, Nandar W, Connor JR. Prolyl-peptidyl isomerase, Pin1, phosphorylation is compromised in association with the expression of the HFE polymorphic allele, H63D. Biochim Biophys Acta. 2010;1802:389-95.
89. Moalem S, Percy ME, Andrews DF, Kruck TP,Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet. 2000;93:58-66.
90. Percy M, Moalem S, Garcia A, Somerville MJ, Hicks M, Andrews D, Azad A, Schwarz P, Beheshti Zavareh R, et al. Involvement of ApoE E4 and H63D in sporadic Alzheimer's disease in a folate-supplemented Ontario population. J Alzheimers Dis. 2008;14:69-84.
91. Robson KJ, Lehmann DJ, Wimhurst VL, Livesey KJ, Combrinck M, Merryweather-Clarke AT, Warden DR, Smith AD. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet. 2004;41:261-5.
92. Pulliam JF, Jennings CD, Kryscio RJ, Davis DG, Wilson D, Montine TJ, Schmitt FA, Markesbery WR. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet. 2003;119B:48-53.
93. Sampietro M, Caputo L, Casatta A, Meregalli M, Pellagatti A, Tagliabue J, Annoni G, Vergani C. The hemochromatosis gene affects the age of onset of sporadic Alzheimer's disease. Neurobiol Aging. 2001;22:563-8.
94. Combarros O, Garcia-Roman M, Fontalba A, Fernandez-Luna JL, Llorca J, Infante J, Berciano J. Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer's disease. Dement Geriatr Cogn Disord. 2003;15:151-4.
95. Correia AP, Pinto JP, Dias V, Mascarenhas C, Almeida S, Porto G. CAT53 and HFE alleles in Alzheimer's disease: a putative protective role of the C282Y HFE mutation. Neurosci Lett. 2009;457:129-32.
96. Lleo A, Blesa R, Angelopoulos C, Pastor-Rubio P, Villa M, Oliva R, Bufill E. Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:820-1.
97. Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM. Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging. 2004;25:465-74.
98. Candore G, Licastro F, Chiappelli M, Franceschi C, Lio D, Rita Balistreri C, Piazza G, Colonna-Romano G, Grimaldi LM, et al. Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer's disease patients from Northern Italy. Mech Ageing Dev. 2003;124:525-8.
99. Guerreiro RJ, Bras JM, Santana I, Januario C, Santiago B, Morgadinho AS, Ribeiro MH, Hardy J, Singleton A, et al. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 2006;6:24.
100. Blazquez L, De Juan D, Ruiz-Martinez J, Emparanza JI, Saenz A, Otaegui D, Sistiaga A, Martinez-Lage P, Lamet I, et al. Genes related to iron metabolism and susceptibility to Alzheimer's disease in Basque population. Neurobiol Aging. 2007;28:1941-3.
101. Avila-Gomez IC, Jimenez-Del-Rio M, Lopera-Restrepo F, Velez-Pardo C. Association between HFE 187>C.G (H63D) mutation and early-onset familial Alzheimer's disease PSEN-1 839A>C (E280A) mutation. Ann Hematol. 2008;87:671-3.
102. Alizadeh BZ, Njajou OT, Millan MR, Hofman A, Breteler MM, van Duijn CM. HFE variants, APOE and Alzheimer's disease: findings from the population-based Rotterdam study. Neurobiol Aging. 2009; 30:330-2.
103. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology. 1995;45:1138-43.
104. Snyder AM, Connor JR. Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta. 2009;1790:606-14.
105. Costello DJ, Walsh SL, Harrington HJ, Walsh CH. Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: a case report series. J Neurol Neurosurg Psychiatry. 2004;75:631-3.
106. Dekker MC, Giesbergen PC, Njajou OT, van Swieten JC, Hofman A, Breteler MM, van Duijn CM. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci Lett. 2003;348:117-9.
107. Buchanan DD, Silburn PA, Chalk JB, Le Couteur DG, Mellick GD. The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci Lett. 2002;327:91-4.
108. Borie C, Gasparini F, Verpillat P, Bonnet AM, Agid Y, Hetet G, Brice A, Durr A, Grandchamp B. Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol. 2002;249: 801-4.
109. Akbas N, Hochstrasser H, Deplazes J, Tomiuk J, Bauer P, Walter U, Behnke S, Riess O, Berg D. Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci Lett. 2006;407:16-9.
110. Aamodt AH, Stovner LJ, Thorstensen K, Lydersen S, White LR, Aasly JO. Prevalence of haemochromatosis gene mutations in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78:315-7.
111. Halling J, Petersen MS, Grandjean P, Weihe P, Brosen K. Genetic predisposition to Parkinson's disease: CYP2D6 and HFE in the Faroe Islands. Pharmacogenet Genomics. 2008;18:209-12.
112. Biasiotto G, Goldwurm S, Finazzi D, Tunesi S, Zecchinelli A, Sironi F, Pezzoli G, Arosio P. HFE gene mutations in a population of Italian Parkinson's disease patients. Parkinsonism Relat Disord. 2008;14: 426-30.
113. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson's disease. Int J Epidemiol. 1999;28:1102-9.
114. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003;60:1761-6.
115. Dietrich RB, Bradley WG Jr. Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. Radiology. 1988;168:203-6.
116. van der AD, Grobbee DE, Roest M, Marx JJ, Voorbij HA, van der Schouw YT. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke. 2005;36:1637-41.
117. Davalos A, Castillo J, Marrugat J, Fernandez-Real JM, Armengou A, Cacabelos P, Rama R. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology. 2000;54:1568-74.
118. Davalos A, Fernandez-Real JM, Ricart W, Soler S, Molins A, Planas E, Genis D. Iron-related damage in acute ischemic stroke. Stroke. 1994;25:1543-6.
119. Millan M, Sobrino T, Castellanos M, Nombela F, Arenillas JF, Riva E, Cristobo I, Garcia MM, Vivancos J, et al. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke. 2007;38:90-5.
120. Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999;100:1268-73.
121. Njajou OT, Hollander M, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM, van Duijn CM. Mutations in the hemochromatosis gene (HFE) and stroke. Stroke. 2002;33:2363-6.
122. Ellervik C, Tybjaerg-Hansen A, Appleyard M, Sillesen H, Boysen G, Nordestgaard BG. Hereditary hemochromatosis genotypes and risk of ischemic stroke. Neurology. 2007;68:1025-31.
123. Ekblom K, Hultdin J, Stegmayr B, Johansson I, Van Guelpen B, Hallmans G, Weinehall L, Johansson L, Wiklund PG, et al. Iron stores and HFE genotypes are not related to increased risk of ischemic stroke. A prospective nested case-referent study. Cerebrovasc Dis. 2007;24:405-11.
124. Deugnier Y, Mosser J. Modifying factors of the HFE hemochromatosis phenotype. Expert Rev Gastroenterol Hepatol. 2008;2: 531-40.
125. Hashimoto K, Hirai M, Kurosawa Y. Identification of a mouse homolog for the human hereditary haemochromatosis candidate gene. Biochem Biophys Res Commun. 1997;230:35-9.
126. Zhou XY, Tomatsu S, Fleming RE, Parkkila S,Waheed A, Jiang J, Fei Y, Brunt EM, Ruddy DA, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci USA. 1998;95:2492-7.
127. Golub MS, Germann SL, Araiza RS, Reader JR, Griffey SM, Lloyd KC. Movement disorders in the Hfe knockout mouse. Nutr Neurosci. 2005;8:239-44.
128. Tomatsu S, Orii KO, Fleming RE, Holden CC, Waheed A, Britton RS, Gutierrez MA, Velez-Castrillon S, Bacon BR, et al. Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. Proc Natl Acad Sci USA. 2003;100:15788-93.